OCGN Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ocugen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$2.11 |
| 52 Week Low | US$0.36 |
| Beta | 3.77 |
| 11 Month Change | -3.13% |
| 3 Month Change | -30.70% |
| 1 Year Change | 131.77% |
| 33 Year Change | -87.31% |
| 5 Year Change | 151.65% |
| Change since IPO | -68.39% |
Recent News & Updates
Shareholder Returns
| OCGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.9% | -3.7% | 0.3% |
| 1Y | 131.8% | 15.2% | 31.1% |
Return vs Industry: OCGN exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: OCGN exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| OCGN volatility | |
|---|---|
| OCGN Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OCGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OCGN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 65 | Shankar Musunuri | www.ocugen.com |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
Ocugen, Inc. Fundamentals Summary
| OCGN fundamental statistics | |
|---|---|
| Market cap | US$267.58m |
| Earnings (TTM) | -US$51.14m |
| Revenue (TTM) | US$4.70m |
55.8x
P/S Ratio-5.1x
P/E RatioIs OCGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCGN income statement (TTM) | |
|---|---|
| Revenue | US$4.70m |
| Cost of Revenue | US$31.62m |
| Gross Profit | -US$26.91m |
| Other Expenses | US$24.23m |
| Earnings | -US$51.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | -572.66% |
| Net Profit Margin | -1,088.17% |
| Debt/Equity Ratio | 7.1% |
How did OCGN perform over the long term?
See historical performance and comparison